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In the previous paper of this series (1)  it was reported that tubercle bacilli 
susceptible to various drugs in vitro were nonetheless able to survive long con- 
tinued  exposure  to  these  drugs  when residing  within certain  organs  of  the 
mouse. This phenomenon was particularly prominent in the spleen. Irrespec- 
tive of the  degree of influence exerted by a  particular  drug or drug pairing 
during the first week or two of the chemotherapy, the microbial census in the 
spleen would then stabilize. Once stabilized, the census would remain constant 
despite continuation of the chemotherapy for periods as long as 3 to 6 months. 
This persistence of tubercle  bacilli was not a  reflection of the emergence of 
strains drug-resistant in the conventional sense. In the experimental conditions 
maintained, the trend line of the microbial census during chemotherapy was 
characteristic for a  particular drug or drug pairing and was uniformly pre- 
dictable for both lung and spleen. Only in the spleen, however, was the phe- 
nomenon of microbial persistence easily demonstrable thus indicating a signifi- 
cant difference in the drug-parasite-host relationships which obtained in the 2 
organs.  It  should  be  noted  that  this  phenomenon  of  microbial  persistence 
throughout chemotherapy was observed even when the total census of tubercle 
bacilli in the spleen was quite low, as was the case, for example, during the 
administration of isoniazid. 
The persistence in the spleen during chemotherapy of a  constant census of 
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otherwise  drug-susceptible tubercle  bacilli, occurred  uniformly with  10  anti- 
microbial drugs  1 known  or reported  to  have  antituberculous  activity in  ~ivo 
(2). Among the 10 drugs studied were all those commonly used in clinical prac- 
tice and  they were used  singly, in various pairs, and  in some  cases in  triple 
drug regimens. This persistence of tubercle bacilli in the spleen despite appro- 
priate  chemotherapy  has  been  significantly  altered  only  by one  drug,  the 
nicotinamide derivative, pyrazinamide (1,  3).  This influence of pyrazinamide 
has  been  uniformly reproducible only when  it is administered in  association 
with another antituberculous drug. 
The capacity of pyrazinamide and a  companion drug to reduce populations 
of tubercle bacilli in  the mouse  to  below the point of detectability has  been 
designated "vanishing." Observations designed to define this unique phenome- 
non form the basis of the present report. 
Materials and Methods 
MC~robial Enumeration  TecknCque.--The  technique for microbial enumeration employed 
was that originally described by Fenner, Martin, and Pierce (4), and has been described in 
detail in the preceding  paper of this series  (1). In its essentials,  the procedure con-qlsts of 
infecting large numbers  of mice (male albino mice, Webster Swiss strain) by the intravenous 
route with strains of tubercle bacilli of human origin. The strains of M. tuberculosis used were 
the H37Rv strain and several others recently isolated from patients with pulmonary tuber- 
culosis. Infection was carried out by intravenous inoculation with 0.2 ml. of a  10  -1 dilution 
of culture in 0.1 per cent bovine albumin. Immediately after infection the animals were as- 
signed to various experimental groups. At appropriate intervals after the start of infection, 
3 or more mice were removed from each experimental group and sacrificed. The lungs and 
spleens were homogenized and cultured by quantitative techniques.  The actual enumeration 
of colonies of tubercle bacilli and the calculations involved are described in the previous 
report (1). 
The census of culturable tubercle bacilli within an organ was expressed in terms of viable 
units per milliliter of homogenate.  The logarithms of these numbers were plotted graphically 
as a function of time after infection.  The resulting curves are taken to represent the course 
of the tuberculous infection within that organ during the experimental period. 
Lower Limit o/Detectability.--Considering  the dilution which is necessary  for preparing 
the tissue emulsion as well as the limitations of the volume of the organ studied, it is obvious 
that there is a lower limit of the method in terms of ability to detect culturable tubercle 
bacilli. The lower limitations vary with the organ size, the volume of the homogenizing diluent, 
and the number of replicates plated. Accordingly these factors will be specified in qualifying 
the results of certain experiments herein presented. 
Drug Administration  and Dosage.--Except  for streptomycin, the drugs were administered 
in the diet by the thorough mixing of finely ground pellets of diet with amorphous drug in a 
MeLelian dry batch mixer. Unless otherwise specified, the dosage of pyrazinamide was 2 per 
cent of the daily diet; the isonlazid dosage was 0.0125 per cent; the para-amino salicylic  acid 
(PAS) dosage was 0.75 per cent. Streptomycin was administered intramuscularly in a single 
daily injection of 4 nag. 
X  The  ten  drugs were:  isoniazid,  streptomycin,  para-amino salicylic acid,  pyrazinam- 
ide,  nicotinamide,  4-butoxy-4'(dimethylamino)thiocarbanilide,  p-isobutoxybenzaldehyde 
thio-semicarbazone,  2-[o-  (2-diethylaminoethoxy) anilino]-N-(p-tolyl) 1,4-naphthoquinoneimine 
monocitrate, thioisonlcotinamide,  and hinconstareh. R.  M.  McCUNE,  JR.,  R.  TOMPSETT,  AND  W.  McDERMOTT  765 
RESULTS 
Repetition  of Observations on Pyrazinamide  and Isoniazid  Administered  To- 
getker.--The first experiments  consisted of a repetition in greater detail of the 
observations  on  the  influence  of  pyrazinamide and  isoniazid  administered 
singly and together on the census of tubercle bacilli in the lungs and spleen of 
mice. Both the infection and the antimicrobial therapy were started on the 
same day. The results of these experiments may be seen in Text-figs. 1 and 2. 
In the lungs of the untreated animals, the population of tubercle bacilli rose 
steadily during the first 3 weeks of the infection  and remained high for the 
remainder of the 118 day period of observation. 
In the treated animals,  the microbial populations fell promptly during the 
first 3 weeks. From that point on, the populations of tubercle bacilli in most of 
the lungs of the isoniazid-treated animals were below the level of detectability. 
In some of these  animals,  however,  tubercle  bacilli  were present  even after 
118 days of therapy. Tubercle  bacilli also persisted  in the animals which re- 
ceived pyrazinamide alone even though the micro-organisms could not usually 
be isolated 8 weeks after the start of therapy. For, in 5 of the 6 pyrazinamide- 
treated animals, tubercle bacilli were easily detectable in the lungs on the 90th 
day of treatment and in one animal the census was at the pretreatment level. 
In  the  spleens  of  the  untreated animals  (Text-fig.  2),  the  characteristic 
early rise in the census with slight fall and then stabilization for the remainder 
of the 118 day period occurred. Under the influence of isoniazid, the microbial 
populations in the spleen likewise behaved as in previous  experiments  (1). A 
steady fall occurred during the first 3 weeks, and the census stabilized and per- 
sisted thereafter for the remainder of the 118 day period. 
With pyrazinamide and isoniazid administered together, there were no de- 
tectable tubercle bacilli in the lungs of two of three animals examined 23 days 
after the start of treatment and no tubercle bacilli could be cultured from the 
lungs of any of the animals during the remainder of the experiment. 
In the spleen, during the first 3 weeks of therapy the census curve for the 
animals which received pyrazinamide alone, dropped more slowly than in the 
animals with isoniazid alone and remained thereafter at a level higher than in 
the isoniazid-treated  animals. 
The behavior of the splenic populations of tubercle  bacilli  in the animals 
which  received  pyrazinamide and isoniazid  together was  distinctly different 
from that in the animals which received either drug alone. At the outset (first 
16 days of chemotherapy) the pyrazinamide appeared to antagonize the action 
of the isoniazid.  Both drugs  were being given together, yet only  the same slight 
fall in census occurred  which was observed  with the administration of pyra- 
zinamide alone. This was in contrast to the substantial drop in census which 
occurred with the use of isoniazid alone. By the end of the 3rd week, however, 
the populations of tubercle bacilli in the spleens of the pyrazinamide-isoniazid 
animals had begun to fall.  Sampling on the 37th day revealed  no detectable o  (o 
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organisms  in the spleen on one of three animals,  and  thereafter no tubercle 
bacilli  could be cultured from the spleens of any of the animals at any of the 
observation points. 
Pyrazinamide-Isoniazid  and  Isoniazid-Streptoraycin-PAS.--The  effective- 
ness of the pyrazinamide-lsoniazid  regimen  was compared in a  single experi- 
ment with the effectiveness  of a  triple drug regimen  comprised of all 3 of the 
antituberculons  drugs in general use,  i.e., isoniazid,  streptomycin,  and pare- 
amino salicylic acid (PAS). 
The techniques used during the first 90 days of this experiment permitted the detection of 
75 to 90 microorganisms per organ. On day 118 of the experiment, however, a  technique of 
considerably increased sensitivity was substituted and is described in detail in a  subsequent 
section. As few as 1 to 3  tubercle bacilli were theoretically detectable in each organ. The 
results of this experiment may be seen in Text-figs. 3 and 4. 
In the lungs with the triple drug regimen (Text-fig.  3) the microbial census 
fell so that, with a single exception,  no tubercle bacilli could be cultured after 
the 5th week of therapy. Only the less sensitive detection method was used in 
these particular  observations.  On  the  last  day of the  experiment,  however, 
after 17 weeks of treatment with the triple drug regimens,  the more sensitive 
cultural method revealed the presence of tubercle bacilli  in 7 of the 8 animals 
examined.  In  contrast,  in  the  animals  which  received  the  pyrazinamide- 
isoniazid  regimen  no tubercle bacilli  were detectable in the lungs even at the 
termination  of the experiment when the more sensitive cultural method was 
used. 
In the spleens  (Text-fig.  4), tubercle bacilli  persisted throughout the entire 
13 week period of therapy with the triple drug regimen of isoniazid,  streptomy- 
cin, and PAS. With the pyrazinamide-isoniazid  regimen,  however, no tubercle 
bacilli  could be cultured from the spleens  of any of the animals at any time 
subsequent to the 57th day of the 118 day treatment period. 
Effectiveness in Established Infections.--When the start of pyrazinamide or 
isoniazid,  used singly,  was withheld  for a  21  day period after infecting  the 
mice with tubercle bacilli,  there was a reversal in the relative effectiveness  of 
the two drugs on the populations of tubercle bacilli in the spleen  (Text-fig.  5). 
21 days after infection,  the population of tubercle bacilli  in the spleens of un- 
treated animals had stopped increasing  and the census was beginning to show 
a fall. By the 5th week after infection,  the populations had become essentially 
stable, but a very slight fall occurred steadily during the remainder of the 100 
day experiment. 
The initiation of isoniazid therapy 21 days after the start of the infection re- 
snlted in a fairly sharp fall in the splenic census of tubercle bacilli with stabili- 
zation of the census thereafter.  When pyrazinamide  therapy was first intro- 
duced 21 days after the start of infection,  the populations of tubercle bacilli 
fell promptly and the census reached lower levels than in the isoniazid-treated c~ 
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animals.  In some of the pyrazinamide-treated animals the census stabilized 
after the initial fall and remained  constant for the period  of observation.  In 
other pyrazinamide-treated animals,  however,  the initial fall continued,  and 
in some of the animals tubercle bacilli could not be recovered at the end of the 
experiment. 
The  initiation of pyrazinamide and isoniazid  together,  21  days after the 
start of the infection,  was followed by a  steady fall in the splenic census of 
tubercle bacilli. The drop in census could be measured during the first 35 days 
after the start of pyrazinamide-isoniazid  therapy, but fell below the limits of 
detection thereafter. Throughout the remaining 44 days of the experiment,  it 
was not possible to culture tubercle bacilli from the spleens of any of the pyra- 
zinamide-isoniazid-treated animals,  even  with the use of the more sensitive 
cultural technique. 
No antagonism of isoniazid action by the pyrazinamide was demonstrated 
in the 21 day infection. As pyrazinamide exerted the stronger effect in reducing 
the populations  in these circumstances,  however,  any antagonism of the iso- 
niazid  would  presumably  not  have  been  perceptible. 
In the lungs of the untreated animals, 21 days after start of the infection, the 
populations  of tubercle bacilli had stopped increasing and the puimonic census 
remained stable throughout the remaining  79 days of the experiment  (Text- 
fig. 6). As in the spleen, the fall in census when pyrazinamide alone or pyrazina- 
mide and isoniazid were first administered at this 21 day point was appreciably 
greater than occurred with the use of isoniazid alone. 
As may be seen in Text-fig. 6, during the first 35 days of treatment of the 21 
day old infection, an identical  fall in census occurred in the lungs of the ani- 
mals which received pyrazinamide  alone and in those which received pyrazinam- 
ide-isoniazid. From this point on,  the populations  of tubercle  bacilli dropped 
below the limits of detectability in the animals which received the pyrazinam- 
ide-isoniazid regimen and  the  bacilli  were  likewise undetectable in  one-half 
of the animals  which  received  pyrazinamide alone.  In contrast to  this  dis- 
appearance  of the tubercle bacilli which occurred with pyrazinamide-isoniazid, 
and in some instances with pyrazinamide alone, the bacilli could be cultured, 
at every observation  point, from the lungs of the animals which received iso- 
niazid alone.  ~  For the final determinations in this experiment (i.e.  census of day 
!00),  six or seven animals were used in each group  except for the untreated 
group. 
Thus, the end result of the influence of pyrazinamide-isoniazid on the census 
of tubercle bacilli in both the spleen and the lung was identical when started on 
the 1st day of infection or 21 days thereafter. The relative degree of influence 
of the individual drugs was different, however, in the 2 infections of different 
length. Pyrazinamide regularly exerted  a  greater effect than isoniazid  when 
The more  sensitive culturing technique was used in these studies. f~ 
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the infection had been present for 21 days before chemotherapy was started. 
The results with pyrazinamide alone were irregular when the infection and the 
chemotherapy were started on the same day. In some such experiments, the 
populations of tubercle bacilli in  the  lungs and spleen remained at  the pre- 
treatment census whereas in other experiments the tubercle bacilli "vanished." 
Isoniazid-Streptomycin  in  21  day  Infection.--For  a  comparison  with  the 
pyrazinamide-isoniazid results in the 21 day infection, experiments were con- 
ducted in which isoniazid and streptomycin together were first administered 
21 days after the start of infection. The results of these experiments may be 
seen in Text-figs. 7 and 8. 
Unlike the situation with pyrazinamide-isoniazid, in no instance did isonia- 
zid,  streptomycin,  or  isoniazid-streptomycin  reduce  the  census  of  tubercle 
bacilli to below the limits of detection when chemotherapy was first started 21 
days after infection. This was observed regularly in both the spleens and the 
lungs of the 21 day infected mice treated for 79 days thereafter. 
As in the previous experiment, the influence of isoniazid alone in the 21 day 
infection was quantitatively less than when the administration of the drug was 
started on the 1st day of infection. This lessened influence of isoniazid in the 
more advanced infection was apparent both in the lung and in the spleen. The 
effectiveness of streptomycin on the tubercle bacilli in the lung was not appre- 
ciably lessened, however, when the drug was first administered 21 days after 
the start of infection. Indeed, there was a moderate fall in census during strepto- 
mycin administration,  in contrast to  the  stable  census observed in previous 
experiments (1) in which streptomycin was started on the 1st day of infection. 
When isoniazid-streptomycin therapy was initiated 21  days after the start 
of the infection, the behavior of the lung populations of tubercle bacilli was 
the same as when the chemotherapy and the infection were started on the same 
day (Text-fig. 7). The census of tubercle bacilli in the spleen did not fall below 
the limits of detection during the 79 day period of treatment but it showed a 
slow steady fall. This fall was still apparent at the time the observations were 
terminated 100 days after the start of the infection (Text-fig. 8). The extent 
of this fall with isoniazid-streptomycin therapy, however, was not at all com- 
parable with the fall in census observed with pyrazinamide-isoniazid in either 
the beginning or the older tuberculous infection. It should also be noted in this 
connection, that in the untreated animals,  the populations of tubercle bacilli 
fell by approximately  1  logarithm unit  from  the  maximum  census attained 
shortly before therapy was started on the 21st day after infection. 
Pyrazinamide-Isoniazid  Compared  with  Isoniazid-Streptomycin-PAS  in 
the 21 Day Infection.--An experiment was conducted to compare the effective- 
ness of pyrazinamide-isoniazid with  that of the triple dr~g regimen, i.e.,  iso- 
niazid, streptomycin, and PAS, when chemotherapy was first started 21 days 
after the start of the tuberculous infection. The results of this experiment may 
be seen in Text-figs. 9 and  10. With  the pyrazinamide-isoniazid regimen, no ;O 
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organisms could be cultured from either the lungs or the spleens of any animals 
subsequent  to  the 56th  day of treatment,  with  the  exception of the  lung of 
one of eight animals cultured on the 79th day of treatment.  In contrast,  the 
populations of tubercle bacilli in  the animals  which received  the  triple  drug 
regimen remained  above the  limits  of detectability  in  both  lung and  spleen 
with but a single exception throughout the entire 100 day experimental period. 
Attempts to Establish  the Presence  of Tubercle  Bacilli in the Mouse  Tissues 
Yielding No  Tubercle Bacilli on Culture.--Four procedures were employed in 
an effort to  increase  the  recovery of tubercle  bacilli from the  spleens  of the 
animals which received wrazinamide and a  companion drug. The procedures 
were: an elaboration of the basic technique by the inclusion of more animals, 
a  reduction of the quantity of diluents used for homogenizing, and the addi- 
tional practice of culturing virtually all of an organ rather than aliquots; the 
inoculation of guinea pigs with  homogenates of the  spleens  of the pyrazina- 
mide-treated mice; the continued incubation in vitro (for 9 months) of cultures 
of  the  homogenates following a  technique  introduced  by Hobby et al.  (6); 
and the maintenance of the animals for a  90 day treatment-free period before 
sacrifice and examination of the tissues. 
Elaborations  of Technique.- 
The methods castomarfly employed in the  present study for enumeration of tubercle 
bacilli in the animal tissues permit detection of 70 to 90 organisms  per lung or spleen depending 
upon the size of the organ. Accordingly,  the amount of diluent used for homogenizing  the 
organs was reduced, and as much of each total homogenate as was practically possible was 
spread on the surface of the culture medium. As a consequence, the sensitivity of the tech- 
nique was increased to the point at which the recovery  of as few as 1 to 3 culturable tubercle 
bacilli per lung or spleen was possible. The possibility existed that the tissue extracts in the 
more concentrated homogenates might contain substances inhibitory for tubercle bacilli. A 
tenfold dilution of these homogenates, however, yidded a proportionate tenfold difference 
in counts. Moreover, when known numbers of tubercle bacilli were added to splenic and pul- 
monic homogenates, from 32 uninfected animals, it was possible to obtain positive cultures 
with regularity when so few as 1 or 2 viable units per individual spleen had been added. Eight 
of these uninfected animals had received pyrazinamide and isoniazid either singly or together 
until the time of sacrifice. 
In the latter phases of the experiments when it was no longer possible to culture tubercle 
bacilli from the pyrazinamide-isoniazid-treated animal tissues, the numbers of animals sam- 
pled from these groups were increased from the usual 3 to 8, thus increasing the significance 
of the disappearance of the microorganisms  from the tissues. 
An example of the results of these daborations of the technique may be seen 
in  the  experiment  presented  in Text-fig. 3.  With  the use of the  original less 
sensitive  technique,  no  tubercle  baciUi  could  be  cultured  from the  lungs  of 
any of the animals after the 3rd week of treatment with the triple drug regimen 
of isoniazid,  streptomycin, and PAS. When the more sensitive technique was 
employed after 17 weeks of treatment, however, it was possible to culture tu- 
bercle bacilli from the lungs of a11 of the animals examined. Nevertheless, when 780  ~FATE Or  MYCOBACTERILr~  TUBERCULOSIS  IN  TISSUES 
pyrazinamide and isoniazid were used together, no tubercle bacilli were demon- 
strable  in  the lungs  or spleens of  any of  the  animals after the 8th  week  of 
treatment even when the more sensitive technique was employed. 
Guinea Pig Inoculation.--A  5-month experiment, to  be described in detail 
below, was set up to determine the length of the period of pyrazinamide ad- 
ministration  in  the  pyrazinamide-isoniazid  regimen,  which  was  necessary  to 
result  in  the  disappearance  of  the  tubercle bacilli. 
Aliquots of  splenic homogenates from  representative animals of  each treatment group 
used  in this experiment were  inoculated subcutaneously into guinea pigs.  The cutaneous 
reaction of the guinea pigs to tuberculin was determined 30 days after infection, and the 
animals were examined post  mortem  2  months after infection.  Gross and histopathologic 
studies were performed. 
In  the  guinea  pigs  inoculated  with  tissues  from mice which  had  received 
isoniazid  or pyrazinamide singly or pyrazinamide-isoniazid for only 2  weeks 
with  isoniazid alone thereafter,  the  cutaneous reaction  to tuberculin  became 
positive and  the  characteristic  lesions  of  tuberculosis  were  demonstrable  on 
postmortem examination. In contrast,  both the tuberculin reaction and post- 
mortem examination failed to reveal any evidence of tuberculous infection in 
the  guinea  pigs  inoculated  with  spleens  from mice  which  had  received  the 
pyrazinamide component  of  the  pyrazinamide-isoniazid  regimen  for  as  long 
as 8 or 12 weeks. 
Long Continued Incubation in Vitro of Splenic Homogenates from Pyrazinam- 
ide-Treated Animals.--A series of splenic homogenates from which no tubercle 
bacilli could be cultured by customary techniques was subjected to long con- 
finued incubation in tween-albumin medium by a technique reported by Hobby 
and her associates (6).  Subcultures of these emulsions after 9 months of incu- 
bation failed to reveal any tubercle bacilli. 
Prolonged Posttreatment Observation.--The  results  of  the  experiments  in 
which  prolonged posttreatment  observation was employed to  determine  the 
presence of tubercle bacilli may be seen in Table I. 
Groups of mice received 90 or 120 day periods of pyrazinamide-isoniazid  therapy starting, 
On the day of infection with tubercle bacilli. At the completion of the antimicrobial therapy 
microscopy and culture of the lungs and spleens of sample subgroups failed to reveal any 
tubercle bacilli even with the use of the more sensitive technique. The remaining animals in 
the groups were then observed for a 90 day treatment-free interval before sacrifice and culture 
of the tissues, 
In the animals treated for 90 days, tubercle bacilli were cultured from spleens 
of twelve of the thirty animals examined after the 90 day treatment-free inter- 
val.  In  one  of  these  thirty  animals,  culture  of  the  lungs  likewise  revealed 
tubercle bacilli. Of the eleven animals treated on the 120 day regimen, tubercle 
bacilli were cultured from both the lung and spleen of one animal, and the re- 
maining animals yielded no tubercle bacilli on culture of either lung or spleen. R.  M.  McCUNE,  J'R.,  R.  TOMPSETT~  AND  W.  McDERMO'rI'  781 
In the thirteen of the total of forty-one animals from which tubercle bacilli 
could  be  recovered,  the  total  populations  were  small,  a  mean  of 2.5X  10  ~ 
culturable units per lung and 6.4 X  10  ~ culturable units per spleen. All 9 of the 
strains  which  were  tested  under  appropriate  conditions  in ~itro (5,  8)  were 
susceptible  to pyrazinamide and to isoniazid to the same degree as the parent 
strain used to produce the infection. 
TABLE I 
Microbial Populations (H371~) in Spleens and Lungs of 41 Mice 13 Weeks after Disconlinuing 
Pyrazinamide-Isoniazid Treatment 
90 d~y  treatment 
Animal No.  Splee~  Luug 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13-30 
3.3 X  i0  s 
3.1 X  105 
1.1X 10  s 
5.6 X  10  s 
1.9 X  10  s 
1.9 X  10  s 
1.4 X  10  l 
1.4 X  10  s 
1.2 X  10  a 
1.0 X  10  s 
9.6 X  10= 
1.3 X  102 
0 
3.5 
0 
0 
×  10  ~ 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
120 day treatment 
1  [  6.8 X  104  [  1.5 X  10= 
2-11  [  0  [  0 
Populations  of M. t~berculosis (H37Rv) in mouse tissues 13 weeks after cessation of a 13 
and  17 week course  of pyrazinamide-isoniazid  treatment.  Infecting  inoculum:  2.8 X  106 
culturable  units of tubercle bacilli. 
This method of prolonged posttreatment  observation was the only method 
discovered  by  which  the  continued  presence  of  tubercle  bacilli  in  certain 
of the animals which received pyrazinamide-isonlazid could be demonstrated. 
Examination of Tissues Other Than Lung or Spleen.--The possibility existed 
that the failure to demonstrate any tubercle bacilli in the spleens and lungs of 
mice  which  received  pyrazinamide-isonlazid  therapy  did  not  reflect  the  dis- 
appearance  of  the  microorganisms  from  other  tissues  of  the  same  animals. 
In this case, posttreatment relapse need not necessarily occur in situ but might 
merely represent a reseeding of the spleen with tubercle bacilli from some focus 
persistent elsewhere. 782  FATE  OF  MYCOBACTERIUM TUBERCULOSIS IN  TISSUES 
Accordingly a group of ten mice infected intravenously with tubercle bacilli 
were treated for 90 days with pymzinamide and isoniazid and were sacrificed. 
At autopsy, in addition to the lungs and spleen, the liver, the kidneys, and the 
inguinal,  axillary, cervical, apd tracheo-bronchial lymph nodes were removed 
and  homogenized. With  the  use  of  the  more  sensitive  culturing  technique, 
there were no tubercle bacilli demonstrable in any of these tissues by culture or 
by microscopy. 
Infection  with a Wild Type Strain of M. tuberculosis.--As  all of the experi- 
ments presented thus far and all those in the preceding report (1) were con- 
ducted with the stock H37Rv strain of tubercle bacilli, the influence of pyra- 
zinamide and isoniazid on a wild type strain of tubercle bacilli was studied. 
The used strain was isolated from the sputum of a previously untreated patient with far 
advanced pulmonary tuberculosis. Subcultures of the strain were regularly inhibited by iso- 
niazid concentrations of 0.063 ~tg. per ml. The wild type strain was as virulent for mice as the 
H37Rv strain. In fact, it was perhaps slightly more virulent as judged by the failure of any 
untreated animals to survive 12 weeks after infection. 
The influence of pyrazinamide and isoniazid alone and together on the pul- 
monic and  splenic populations of tubercle bacilli  in mice  infected with  this 
wild type strain may be seen in Text-figs. 11 and 12. The more sensitive cul- 
turing technique was used on day 56 and day 84 for the organs from the groups 
which  had  received  pyrazinamide  alone  and  pyrazinamide-isoniazid.  There 
were no tubercle bacilli demonstrable in the lungs of any of the treated animals 
after 8 weeks. The behavior of the populations of tubercle bacilli in the spleens 
was similar to that observed in animals infected with H37Rv. 8 weeks after the 
start of pyrazinamide and isoniazid, no tubercle bacilli were demonstrable in 
either the lungs or the spleens of any of the animals examined. In contrast, 
persistent  tubercle  bacilli  were  demonstrable  at  the  12  week  observation 
point in  the spleens of some of the animals  which had  received either drug 
alone. 
Pyrazinamide Alone and Isoniazid  Alone.--The respective influence of pyra- 
zinamide alone and  isoniazid alone on the populations of tubercle bacilli  in 
the spleens of mice in the beginning infection and in the 21 day infection have 
been  described  previously.  The  administration  of  isoniazid  alone  never  re- 
sulted  in  the  disappearance  of  tubercle  bacilli  from  the  mouse  spleens.  In 
contrast, such a disappearance from the spleens (as well as the lungs) was ob- 
served not infrequently following the  administration  of pyrazinamide alone. 
In the 21 day infection, approximately one-half of the animals which received 
pyrazinamide alone would fail to reveal culturable tubercle bacilli on sacrifice. 
When antimicrobial therapy and infection were both started on the same day, 
the administration of pyrazinamide alone for a  12 week period resulted in the 
disappearance of the tubercle bacilli from the spleens of 19 of 32 animals ex- 
amined. 0 
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Antagonism  of Isoniazid  by Pyrazinamide  or Nicotinamide.--In  Text-fig. 2 
it may be noted that  during the first 2 weeks of pyrazinamide-isoniazid ad- 
ministration  (when infection and  chemotherapy were started  the  same day) 
the fall in microbial population for the pyrazinamide-isoniazid animals closely 
resembled that observed with pyrazinamide alone, rather than that observed 
with  isoniazid alone in the same  experiment. Accordingly, experiments were 
conducted to discover whether nicotinamide, the parent compound from which 
pyrazinamide is derived, could likewise antagonize the influence of isoniazid. 
This experiment was conducted in the same manner as the previously described 
experiments and both the infection and the chemotherapy were started on the 
same day. The results may be seen in Text-figs. 13 and 14. 
The administration  of nicotinamide alone showed no effect on the  splenic 
population until  the  2nd week; there then occurred a  very slight fall which 
continued as  a  gradual  descent,  throughout  the  12  week  treatment  period. 
The populations of tubercle bacilli in  the lungs of the animals  treated with 
nicotinamide alone  were  comparable with  those present  in  previous  experi- 
ments  with  streptomycin.  When  nicotinamide was  administered along  with 
isoniazid, the effectiveness of the latter drug was significantly less during the 
1st  month  of  treatment  than  when  the  isoniazid  was  administered  alone 
(Text-figs. 13 and 14). 
Thus nicotinamide antagonized the action of isoniazid in the early days of 
the infection in the same way as did pyrazinamide. Nevertheless, the adminis- 
tration  of nicotinamide-isoniazid was  not  followed by  the  vanishing  of  the 
tubercle  bacilli  from  the  tissues  as  had  been  observed  with  pyrazinamide- 
isoniazid. During the last 2 months of treatment with nicotinamide-isoniazid, 
the microbial censuses in both  the lungs and spleens of the  treated animals 
were similar to those determined in the animals which had received isoniazid 
alone. 
Companion Drugs Other Than Isoniazid.--Experiments  were  conducted in 
which  other antimicrobial  drugs  were  substituted  for isoniazid as  the  com- 
panion  drug  for  pyrazinamide.  The  drugs  used  were  streptomycin,  para- 
aminosalicylic acid  (PAS),  and  oxytetracycline. The conditions of these ex- 
periments were otherwise identical with those described above in which infec- 
tion  and  chemotherapy were  started  on  the  same  day. 
The  populations  of  tubercle  bacilli  in  the  spleens  of  the  animals  which 
received  pyrazinamide-streptomycin,  pyrazinamide-PAS,  or  pyrazinamide- 
oxytetracycline all showed the same steady fall to below the limits of detection 
as was the case when isoniazid had been used as the companion drug for pyra- 
zinamide. Thus, in the experimental system employed (infection and chemo- 
therapy  started  together  but  without  a  posttreatment  drug-free  interval) 
any one of the 4  drugs isoniazid,  streptomycin, PAS,  or oxytetracycline ap- 
peared to be indistinguishable from the others in terms of effectiveness as a i  ! 
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companion drug for pyrazinamide. It is of interest that oxytetracycline when 
administered alone showed little if any influence on either the lung or spleen 
populations of tubercle bacilli in the experimental system. Moreover, the uni- 
form  disappearance  of  the  tubercle  bacilli from  the  spleens  of  the  animals 
TABLE II A 
Comparative Effects of Varied Intervuls of Pyrazinamide in  Combination with Isoniazid  on 
Microbial Populations (H37Rv) in Mouse Lungs during 13 Weeks of Treatment 
Contml 
5.5 X  10  8 
9.4X  10  7  1.5X  101 
6.2 X  l0  T  0 
0 
0 
0 
0 
0 
0 
0 
0 
Percentage  of animals 
with  no  culturable 
organisms ...... 
Isoniazid  Pyrazinamide 
13 wks.  13 wks. 
I.I X  104  1.4X  i0  a 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  --*  0 
0  0  --* 
85  92  100  I00  100  100 
The  comparative effects  of  varied periods of pyrazinamide administration  (isoniazid 
administration kept constant) on populations of M. tuberculosis (H37Rv)  in mouse  lungs 
during 13 weeks of therapy. Infecting inoculum: 2.3 X  105 cultumble units of tubercle bacilli. 
* Contaminated culture plate. 
which  received pyrazinamide-PAS occurred  at  a  time  after  the  start  of  in- 
fection (5th to 8th week) at which when PAS was used alone it has apparently 
lost its effectiveness (1). The respective values of these 4  drugs as companion 
drugs for pyrazinamide has not yet been studied in the 21  day infection or in 
the experimental system with the 90 day posttreatment observation period. 
Strains of Tubercle Bacilli Resistant  to Isoniazid  in Vitro.--The  influence of 
isoniazid as  a  companion  drug  for  pyrazinamide was  studied in  animals in- 
fected with isoniazid-resistant strains of tubercle bacilli. R.  M.  McCUNE, JR.,  R.  TOMPSETT, AND W.  McDERMOTT  789 
The two strains  used had both been isolated from patients with pulmonary  tuberculosis 
who had continued to discharge tubercle bacilli after prolonged therapy with isoniazid alone 
(7). In conventional  drug  susceptibility  tests in vitro, strain Rk was resistant  to isoniazid 
concentrations  of 0.25/~g. per mi. and strain  Tit was resistant  to concentrations  of 6.3  #g. 
per ml. Quantitative studies revealed that 68 per cent of strain Rk consisted of tubercle bacilli 
TABLE I5 B 
Comparative Effects  of Varied  Intervals  of Pyrazinamlde in  Combination  with  Isoniazid on 
Microbial Po ,ulations (H37Rv)  in Mouse Spleens during 13 Weeks of Treatment 
Percentage  of ani- 
mals  with  no! 
culturable  or- 
ganisms.. 
Control 
1.4 X  108 
1.2 X  106 
1.2 X  10  ~ 
Isoni~id 
13 wks. 
5.2 X  103 
4.6 X  103 
2.8X  108 
2.7 X  10  ~ 
2.3 X  103 
2.2X  10  3 
1.6 X  103 
1.3  X  103 
1.2 X  103 
5.2 X  102 
5.2 X  10  2 
3.9 X  10  2 
3.6 X  10  2 
2.0 X  102 
Pyrszinv.mide  !i  13 wks. 
2.1X  I0  s  5.5X  103 
1.1  X  105  2.1  X  10  ~ 
4.5X  104  2.0X  103 
4.3X  104  1.8X  103 
~*  1.7 X  108 
0  1.3 X  10  z 
0  5.2 X  102 
0  3.9 X  102 
0  3.2 X  102 
0  3.1X  102 
0  2.8 X  102 
0  2.4X  102 
0  7.5 X  101 
0  --* 
0  ~* 
69  0 
~  ]  ~ 
6.8 X  102  0  C 
1.0 X  102  0  {~ 
6.9 X  101  0  C 
5.2 X  I0  t  0  {~ 
5.2 X  I0  x  0  C 
0  0  C 
0  0  C 
0  C  C 
0  0  C 
0  C  ¢ 
0  0  C 
0  C  £ 
0  C  C 
0  C  C 
0  C  ( 
67  10C I0( 
The comparative effects of varied periods of pyrazinamide  administration  (isoniazid ad- 
ministration  kept  constant)  of populations  of M.  tubercvJosis (H37Rv)  in mouse  spleeus 
during 13 weeks of therapy.  Infecting inoculum: 2.3 X I0  s culturable units of tubercle bacilli. 
* Contaminated  culture plate. 
susceptible to isoniazid concentrations  of 1 #g. per nil. whereas all the ceils of strain  Th were 
resistant  to this concentration  of drug. 
The results observed from the use of pyrazinamide alone in these isoniazid- 
resistant  infections were in  no  way different from  those in  the  isoniazid-sus- 
ceptible infections previously described.  The use of isoniazid as a  companion 
drug to the pyrazinamide, however, failed to result in the disappearance of the 
tubercle bacilli from  the spleens of the  animals  infected with  either of  these 
drug-resistant strains. 790  FATE  0~"  MYCOBACTERIU~  TUBERCULOSIS  IN  TISSUES 
Time-Dose Relationships of Pyrazinamide Necessary  to Produce Pyrazinam- 
ide-Companion  Drug  Phenomenon.--In  all of the  experiments in the  present 
and preceding investigations (1)  in which the administration of pyrazinamide 
and a  companion drug  resulted in the  disappearance  of  the  tubercle bacilli 
from the mouse spleens, the daily dosage of pyrazinamide had been 2 per cent 
TABLE II C 
Comparative Effects of Varied Intervals of Pyrazinamide in Combination with Isoniazid on 
Microbial Populations (tt37Rv) in Mouse Lungs during 27 Weeks of  Treatment 
Percentage  of  animals 
with  no  culturable 
organisms. 
Control  Isoniszid  27 wks. 
3.0 X  l0  s 
1.5 X  10  s 
4.3 X  10  ~ 
0  93 
3  X  100 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
,,iol 
Pyrazinamide  ~i  27 wks. 
6.9X 10  ~  1.9X 101 
3.1  X  103  0 
5.2 X  101  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
75  92 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  0  0 
0  * 
100  100  100 
The  comparative  effects of  varied  periods of  pyrazinamide  administration  (isoniazid 
administration kept constant)  on populations of M. tuberculosis (H37Rv)  in mouse lungs 
during 27 weeks of therapy. 
* Contaminated culture plate. 
of the diet and the duration of the pyrazinamide therapy had been at least 12 
weeks.  Accordingly, a  series of experiments was conducted in an attempt to 
obtain information on the minimal pyrazinamide daffy dosage and the mini- 
mal duration of pyrazinamide therapy which were  necessary to produce  the 
uniform disappearance of tubercle bacilli from the spleens of animals receiving 
pyrazinamide and a  companion drug. 
The chemotherapy and the infection were both started  on the same day in these experi- 
ments. Isoniazid was the companion drug used and it was administered daily for a 13 or 27 R.  M.  McCUNE, JR.,  R.  TOMPSETT~ AND W.  McDERMOTT  791 
week period• The pyrazinamide administration, however, was terminated in various groups 
of animals at 2, 4, 8, and 13 weeks respectively. The results of the 27 week experiment may 
be seen in Tables II A to IID. 
As may be seen in Tables II A  to II D,  8  weeks of pyrazinamide with  iso- 
niazid concurrently and thereafter resulted in the uniform disappearance of the 
TABLE IID 
Comparative Effects  of Varied  Intervals  of Fyraslnamide  in  Combination  with  Isoniazid on 
Microbial P~ ,ulatlons (II37Rv)  in Mouse Spleens during 27 Weeks of Treatment 
Control  Isoniazid Pyrazinamide  27 wks.  ~  ~  ~  ~  ~  ~[~  ~ 
3.0 X  10  7  8.4 X  10  z  9.7 X  104  3.1 X  10  z  8.1 X  10  °  0]  £ 
1.1  X  107  1.6X  102  4.7X  104  2.5X  102  8.1X  10  °  (]  £ 
4.2X  10  n  1.5X  10  ~  8.9X  102  1.2X  102  8.1X  10  °  ~]  £ 
1.4X  10  ~  7.5 X  103  1.2 X  102  8.1  X  10  °  G  £ 
1.4X  10  ~  6.2X  10  a  1.OX  I02  0  0  £ 
1.2X  10  ~  4.8X  10  a  9.5X  101  0  0  £ 
1.0 X  102  0  7.1  X  101  0  0  G 
5.4 X  101  0  6.8  X  101  0  0  (] 
5.4  X  101  0  4.2  X  101  0  0  {] 
4.6X  101  0  2.7X  101  0  01  C 
I 
2.7 X  101  0  1.9 X  101  0  0  (~ 
2.7 X  101  0  0  0  0  C 
2.3 X  101  0  {] 
8 ×  10  °  0  0 
Percentage  of ani- 
mals  with  no 
culturable or- 
ganisms.  0  0  50  8  73  100 I0~ 
The comparative effects of varied periods of pyrazinamide administration (isoniazid ad- 
ministration kept constant)  on populations of M.  tuberculosis  (H37Rv)  in mouse  spleens 
during 27 weeks of therapy. 
tubercle bacilli from the spleens at the completion of the total 13 week  period 
of chemotherapy.  When  the  total  13  week period of chemotherapy  included 
only a  4  week period of pyrazinamide, the results were not uniform;  when the 
pyrazinamide was  given for only  2  weeks  the  results  were  indistinguishable 
from those observed with the use of isoniazid alone. The necessity for admin- 
istering the pyrazinamide for at least 8  weeks was the same whether the total 
period of isoniazid therapy was 13 weeks or 27 weeks. 
It  should  be  noted  that  in  all  experimental situations  in  the  total  study 792  FATE  OF  ~YCOBACTEP,-I'U~ TUBERCULOSIS  IN  TISSUES 
(including those just presented),  in which the populations  of tubercle  bacilli 
uniformly disappeared from the lung and spleen, the total period of antimicro- 
bial therapy has been at least 12 weeks. No experiments have been performed 
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T~x¢-Fm. 15. Influence of various dosages of pymzinamide used alone and with isoniazid 
on populations of tubercle bacilli (H37Rv) in mouse spleens after 84 days of therapy. 
Infecting inoculum 5.3 X  106 culturable units of tubercle bacilli. O, control; A, isoniazid; 
~1, pyrazinamide 0.125 per cent plus isoniazid; ~, pyrazinamide 0.125 per cent plus isoniazid; 
1~, pyraz/namide 0.5 per cent; ®, pyrazinamide 0.5 per cent plus isoniazid; n, pyrazinamide 
2.0 per cent;  O, pyrazinamide 2.0 per cent plus isoniazid. 
in which pyrazinamide and isoniazid were administered together for an 8 week 
period with no chemotherapy thereafter. 
Daily Dose of  Pyrazinamide.--In another experiment, the daily  dose of pyra- 
zinamide was reduced to one-fourth and one-sixteenth the dose used in the pre- 
vious experiments. Infection and chemotherapy were started on the same day 
and the pyrazinamide-isoniazid was continued for the total period of 12 weeks. 
The results  of this experiment  may be seen in Text-fig. 15. R.  M.  McCUNE,  JR.,  R.  TOMPSETT,  AND  W.  McDERMOTT  793 
TABLE  III 
Influence  of Sequential  Administration Pyrazinamide  and Isoniazid on Microbial  Populatigns 
(H37Rv) in Mouse Tissues during 12 Weeks of Treatment. Effect of Discontinuing  Treatment 
for an Additional  12 Weeks 
I  8 wks.  12 wks.  24 wks. 
Group 
Spleen  Lung  Spleen  Lung  Spleen  Lung 
A 
Pyrazinamide 8  5.5 X  10  s  0  7.0 X  10  s 
wks.  0  0  2.4 X  10  2 
[soniazid 4 wks.  0  0  0 
B 
Pyrazinamide 4  1.3  X  10  s  0  7.3  X  101 
wks.  0  0  2.7 X  l0  t 
[soniazid 8 wks.  --*  --*  1.1  X  l0  t 
C 
[soniazid8wks.  3.3X  10  8  2.0X  10  3  1.1  X  101 
Pyrazinamide4  2.9 X  10  s  3.4 X  10  3  0.8 X  101 
wks.  2.6X  10  3  1.7X  10  3  0 
D 
[soniazid 4 wks.  8.9 X  102  0  0 
Pyrazinamide 8  0  0  0 
wks.  0  0  0 
0.6X  10  t  6.1X  10  4 
0  3.9 X  10  3 
0  3.4 X  10  3 
2.7 X  10  s 
2.2  X  10  3 
1.9 X  10  3 
0 
0  7.1  X  10  5 
1.6X  10  s  1.6X  10  5 
0.3X  10  t  6.1X  10  ¢ 
2.7 X  10  4 
2.5  X  10  4 
1.4 X  10  4 
5.5 X  10  3 
0  1.9 X  10  5 
0  3.2  )<  10  4 
0  1.6 X  10  4 
3.7  X  10  8 
1.9 X  10  3 
1.3 X  10  3 
0 
0  6.5  X  10  4 
0  4.2  X  10  4 
0  1.6X  10  s 
0 
0 
0 
0 
0 
0 
4.3 X  10  ° 
1.2 X  10  3 
0 
2.6 X  10  s 
a$ 
0 
2.9 X  10  5 
2.8 X  101 
1.4 X  10  4 
7.5 X  10  3 
1.2 X  10  5 
1.8 X  10  4 
5.5  X  10  4 
5.2X  tO  3 
0 
0 
0 
7.1  X  105 
0 
0 
0 
5.7X  10  4 
0 
0 
0 
0 
0 
0 
The influence of sequential administration of pyrazinamide and isoniazid on populations 
of M. tuberculosis (H37Rv) in mouse tissues during 12 weeks of treatment and the effect of 
discontinuing treatment for an additional 12 weeks. 
Infecting inoculum: 1.8 X  l0  s culturable units of tubercle bacilli. 
* Contaminated culture plate. 794  leATE  OF  MYCOBACTERIUM  TUBERCULOSIS  IN  TISSUES 
As may be seen in the figure, when the daily dose of pyrazinamide was re- 
duced by 75 per cent and administered with isoniazid, there were no detectable 
organisms in seven of ten animals. When the daily dose of pyrazinamide was 
lowered by 94 per cent, it was minimally effective when given alone, and when 
administered  with  isoniazid  the  results  were  identical with  those  seen with 
isoniazid alone. 
It appeared, therefore, from these 2 sets of experiments that within a  total 
period of 13 weeks of chemotherapy the minimal duration of the pyrazinamide 
administration must be approximately 8 weeks and the minimal daily dosage 
must be 2 per cent in the diet in order to produce the pyrazinamide companion 
drug phenomenon of the vanishing of the tubercle bacilli with uniformity. A 
similar period of pyrazinamide administration also appeared  to be necessary 
in the 21 day infection. For, tubercle bacilli could frequently be cultured from 
the mouse spleens 4  weeks after the start of pyrazinamide-isoniazid therapy 
even though the bacilli uniformly vanished thereafter. 
P~azi~mide and Isoniazid Administered in Seq~ce.--The respective roles 
of pyrazinamide and the companion drug  were studied in a  series of experi- 
ments  in  which  pyrazinamide and  isoniazid  were  each  administered  singly, 
but in sequence for periods of varied length. 
The antimicrobial therapy was started on the 1st day of infection  and was continued for a 
total period of 12 weeks irrespective of the particular drug regimen employed.  There were 4 
experimental groups of animals: group A received  pyrazinamide  for 8 weeks and isoniazid for 
4 weeks thereafter; group B received pyrazinamide for 4 weeks and isoniazid for 8 weeks 
thereafter; group C received  isoniazid for 8 weeks and pyrazinamide for 4 weeks thereafter; 
and group D received isoniazid for 4 weeks and pyrazinamide for 8 weeks thereafter. The 
results are presented in Table III. 
As may be seen in Table III, the tubercle bacilli had disappeared from both 
the spleens and the lungs of only one group of animals  (group D) after com- 
pletion of the 12 weeks of chemotherapy. From the beginning of the infection, 
this group had received 4 weeks of isoniazid followed by 8 weeks of pyrazinam- 
ide. In the group of animals which differed only in the fact that  this sequence 
of administration of the 2 drugs was reversed (group A), tubercle bacilli could 
be cultured from the spleens of two of the three animals and the lungs of one 
of the three, examined at the 12 week observation point. Tubercle bacilli were 
also demonstrable in the spleens of all but one of the animals in the 2 groups (B 
and C) which had received the pyrazinamide for only 4 weeks. After 12 weeks' 
posttherapy observation,  tubercle bacilli could be cultured from the spleens 
(three of eight animals) and from the lungs (one of eight animals) of the ani- 
mals from the group in which no tubercle bacilli were demonstrable at the com- 
pletion of the chemotherapy (group D). 
DISCUSSION 
From the above observations it may be seen that populations of tubercle 
bacilli of human origin, subjected in vivo to pyrazinamide and a  companion R.  M.  McCUNE,  JR.,  R.  TOMPSETT,  AND  W.  McDERMOTT  795 
drug, vanished from the tissues in so far as could be determined by microscopy, 
culture, or guinea pig subinoculation. In actuality, the vanishing of the bacilli 
did not represent a complete elimination of all tubercle bacilli from the tissues 
of all of the animals. In fact, 90 days after cessation of drug treatment, tubercle 
bacilli could be isolated from approximately one-third of the animals  studied. 
The tubercle bacilli which survived in the animals, despite exposure to pyra- 
zinamide and a  companion drug, were not resistant either to pyrazinamide or 
to isoniazid in the conventional sense except in one instance. In experiments to 
be published elsewhere (8), it was observed that 9 of the 10 strains subjected 
to testing which had been derived from pyrazinamide-isoniazid animals after 
a  90 day treatment-free interval were inhibited by pyrazinamide when tested 
in an acidic environment in dtro. Nine of these same strains were also inhibited 
by isoniazid concentrations of 0.063 #g.  per ml.  when tested in dtro. 
It appears,  therefore, that, despite the marked quantitative difference be- 
tween the pyrazinamide-companion drug regimen and the other chemothera- 
pies with respect to the abolition of tubercle bacilli in mouse tissues, the nature 
of the survival of the bacilli in the two sets of circumstances is the same. In 
both situations,  some bacilli,  whose descendants were drug-susceptible when 
tested in vitro, were nonetheless able  to persist in the mouse tissues despite 
continued chemotherapy. 
In  the  case of the  non-pyrazinamide regimens,  however,  the  "persisting" 
tubercle bacilli could always be detected. The consistent failure of these bacilli 
to  increase in numbers  indicated  that  the  infection would meet  the  criteria 
for  the  designation  "dormant"  in  the  sense  of being  demonstrably present 
although  inactive. With  the pyrazinamide-containing regimens,  the presence 
of any "persisting" tubercle bacilli could not be detected after an appropriate 
period of therapy. Instead, the entire population vanished and the presence of 
"persisters" in  a  portion of the animals could only be shown retrospectively 
after a  90 day treatment-free interval. Thus at the time of the completion of 
treatment,  the  tuberculous infection would  be  said  to have been in  a  truly 
latent state, meaning that it was undoubtedly present in some animals but was 
hidden beyond the reach of the available methods of detection. By its very 
nature the only proof of the presence of true latency is the subsequent reap- 
pearance of the infection in some animals. 
In essence, the difference between the latent and dormant  state typifies the 
difference between the behavior pattern of the populations of tubercle bacilli 
during pyrazinamide-companion drug therapy and all the other chemothera- 
pies which are studied. 
This situation has many parallels in the antimicrobial  therapy of other infections. 
For example, in the pharyngitis of man produced by Group A hemolytic streptococci, 
the administration of sulfonamide  renders the infection dormant whereas penicillin 
renders it truly latent. With sulfonamide, the presence of the streptococci can gener- 
ally be demonstrated by culture throughout therapy, but the infection is inactive as 796  ]~ATE  OF  MYCOBACTERIUM  TUBERCULOSIS  IN  TISSUES 
judged by its absence of progression and possibly lessened communicability. With 
penicillin, the streptococci "vanish" soon after the onset of therapy and cannot be 
cultured from the nasopharynx at the time chemotherapy is stopped. After a treat- 
ment-free interval,  however, the same serologic type of streptococci reappear in the 
pharynx of a minority of persons treated. The size of this minority can be steadily 
diminished by prolongation of the period of chemotherapy.  Presumably with a sub- 
stantial prolongation  (e.g.  6 or 8 weeks), the "persisters"  might be eliminated alto- 
gether. The last named phenomenon, however, might represent natural death of the 
parasites  after prolonged  "physiologic imprisonment" as much as a  complete and 
direct eradicating action of the drug. 
The  difference between  rendering an  infection dormant and  rendering  it 
latent is thus clear cut. What is not clear, however, is whether this difference 
is merely quantitative or whether it reflects the operation of a  qualitatively 
different type of chemotherapeutic action or even some major change in the 
state of the parasite. 
In the present investigation, the true latency of the experimental tuberculous 
infection was established only for the tissues examined, which in most of the 
experiments consisted of only the lungs and spleens. It is possible,  therefore, 
that tubercle bacilli were present in a  readily detectable state in some other 
tissues. In a single experiment in which tubercle bacilli had vanished from the 
lung and spleen, examination of hepatic, renal, and lymphatic tissue likewise 
failed to reveal any bacilli. Moreover, the spleen represents an organ in which 
the survival to drug exposure by tubercle bacilli was easily demonstrable for 
all of the non-pyrazinamide chemotherapies which were studied. 
It should also be recognized that virtually all the results of the present inves- 
tigation are subject to the defects implicit in sampling techniques. Neverthe- 
less,  it is believed that the uniform predictability of the results with respect 
to the disappearance of the tubercle bacilli from the tissues provides consider- 
able assurance that the observations made on samples are valid for the groups 
in their entirety. 
The further possibility cannot be denied that the vanishing of the popula- 
tions of tubercle bacilli represents a widespread alteration of the ability of in- 
dividual cells to grow on artificial media or in guinea pigs, rather than a reduc- 
tion to an extremely low census. A  bacterial population subsisting in tissue 
must be fairly large to be detectable by microscopy of tissue samples. Conse- 
quently, a  population just below the microscopic limits of detection, if ren- 
dered  non-culturable  with  sufficient uniformity, would  vanish  even  though 
the census were still fairly high. With the technics used in the present studies, 
however,  tubercle  bacilli  could  be  cultured  regularly from  the  animals  re- 
ceiving any form of chemotherapy which did not include pyrazinamide. More- 
over, when known numbers of tubercle bacilli were added to tissue emulsions 
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cultures with regularity when so few as one or two culturable units per in- 
dividual spleen had been  added. In the latter instance,  however,  it must be 
recognized that the added bacilli had not undergone any drug exposure when 
introduced into  the  drug-containing  tissue  emulsions. 
This question of an actual census reduction versus  a  widespread  alteration 
of the ability of individual cells to grow in vitro cannot be definitely settled at 
present. Whichever mechanism is responsible for the vanishing,  it is sufficient 
for the purposes  of the present discussion that this phenomenon  of drug-in- 
duced latency is unique to  the pyrazinamide-companion  drug regimen. 
Two questions  arise with respect  to the mechanics of the disappearance  of 
tubercle bacilli from tissues during chemotherapy: First, is the role of isoniazid 
as a companion drug a specific one. Second, are those actions of pyrazinamide 
and the companion drug,  which are essential for the phenomenon, exerted in- 
dependently on separate microbial  cells or are they mutually dependent and 
hence necessarily exerted on the same microbial cell. 
From the present data, a  possibly  specific role of isoniazid in the process 
cannot be completely excluded for the majority of the experiments were made 
with isoniazid as the companion  drug. In the course of these  experiments,  a 
definite interrelationship  among the antimicrobial  activities of isoniazid, pyra- 
zinamide,  and nicotinamide  was observed.  Both nicotinamide and pyrazinam- 
ide antagonized the  population-reducing  effects  of isoniazid  during the first 
2  weeks  of  infection.  Unlike  pyrazinamide,  however,  the  administration of 
nicotinamide thereafter along with isoniazid was not associated with the van- 
ishing phenomenon.  These 3 compounds, particularly nicotinamide and pyra- 
zinamide, have a relatively close structural similarity to one another. 
The apparent  degree  of specificity  in  the interrelationships among the 3 
drugs might indicate that isoniazid likewise played a specific role in the vanish- 
ing phenomenon when administered as a  companion  drug to pyrazinamide. 
Nevertheless,  3 other drugs, streptomycin, para-amino salicylic acid, and oxy- 
tetracycline, likewise were effective as companion  drugs.  These 3 drugs and 
isoniazid are of diverse chemical nature and exert widely different degrees of 
inhibitory activity against tubercle bacilli, both in the particular experimental 
system employed and in all other comparative tests. Indeed, in the present ex- 
perimental system, the anti-tuberculous activity of oxytetracycline when used 
alone was barely detectable.  Despite their heterogeneity, these drugs all serve 
to render a pyrazinamide effect, which  occurs irregularly with pyrazinamide 
alone, into a uniformly predictable  phenomenon.  It seems unlikely, therefore, 
that the role of isoniazid as a  companion drug in the vanishing phenomenon 
is a specific one. By the same token it should be noted that the four companion 
drugs used  with pyrazinamide were demonstrated to be comparable  only in 
the terms of rendering the infection latent when administered along with pyra- 
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interval would be the same irrespective  of companion drug has not yet been 
studied. 
Interpretation of the experimental  observations  is difficult on the question 
of whether the disappearance  of tubercle  bacilli  during chemotherapy prin- 
cipally represents action of pyrazinamide and the companion drug on the same 
microbial  cell or whether the two drugs act separately on different cells. 
It seems clear that at least a portion of the action is on different  cells. A 
small minority of isoniazid-resistant  cells are present in the H37Rv strain of 
tubercle  bacilli.  Small numbers  of pyrazinamide-resistant cells are also  pre- 
sumably present in the H37Rv strain or at least they emerge from this strain 
in v/vo. Hence  it is reasonable  to assume  that such drug-resistant cells were 
originally present  in some of the pyrazinamide-isoniazid  experiments and were 
rendered dead or latent either by one of the drugs acting alone or by the host 
defenses. 
It is tempting to invoke this same explanation for the "vanishing" phenome- 
non as a whole. Pyrazinamide is the major drug in the phenomenon as evidenced 
by the facts that the effect could not be produced without pyrazinamide and 
occasionally occurred with pyrazinamide alone. It could be postulated that the 
principal  role of the companion drug might consist of acting on the tubercle 
bacilli  which  escaped pyrazinamide action because  they were pyrazinamide- 
resistant. With a sufficiently powerful impact of the pyrazinamide on the initial 
population,  even a relatively weak companion drug might be able  to control 
the residual population as long as the chemotherapy were continued. 
The results of a single experiment in which the pyrazinamide and the isonia- 
zid were administered  in sequence have some bearing  on this point. In this 
experiment,  the survivors  of 4 weeks of isoniazid therapy "vanished" during 
the succeeding 8 weeks of pyrazinamide,  whereas the survivors of 4 weeks of 
pyrazinamide failed to vanish during a comparable period of isoniazid adminis- 
tration. This occurred despite the fact that at the 4 week point when the drugs 
were exchanged, the populations  of pyrazinamide survivors to be subjected to 
isonlazid were appreciably  smaller than the populations  of isoniazid survivors 
to be subjected to pyrazinamide. 
The major portion of the tubercle bacilli in these residual populations  repre- 
sented "persisters" with respect to the drug involved and not tubercle  bacilli 
resistant to that drug in the orthodox sense. More than 99 per cent of the iso- 
niazid survivors  at the 4 week period would be expected  to be isoniazid-sus- 
ceptible  on the basis of repeated observations  with the H37Rv strain of tu- 
bercle bacilli in this experimental system (1). A precise estimate of the number 
of pyrazinamide-resistant cells to be expected  among  the pyrazinamide sur- 
vivors cannot be stated. Nevertheless,  the pyrazinamide-resistant cells should 
have been  only a  small  minority as judged by observations  at  the 4-week 
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pyrazinamide-resistant cells among the tubercle bacilli cultured 90 days after 
the cessation of pyrazinamide-isoniazid  therapy. To a  great extent, therefore, 
the difference in effectiveness between the two drugs after they were exchanged 
in  the  sequential  experiments,  consisted of their capacity to  affect tubercle 
bacilli which had been subjected to the influence of the other drug but were 
not resistant to it.  In short,  pyrazinamide was highly effective on isoniazid 
persisters. To this extent, therefore, the observations support the premise that 
both the pyrazinamide and  the  isoniazid act  on the same  microbial cell  in 
causing the disappearance  of tubercle bacilli. 
The observations also suggest that the timing of the exposure of the tubercle 
bacilli to the two drugs is important and that exposure to the isoniazid must 
precede  or  accompany,  rather  than  follow,  exposure  to  the  pyrazinamide. 
This is of interest in view of the recent observations of Koch-Weser on the 
action of isotopically labelled isoniazid in the presence of other antituberculous 
drugs  (9).  He  has  shown that the effect produced by isoniazid on tubercle 
bacilli (H37Rv) in vitro in the presence of streptomycin is distinctly different 
when exposure to the streptomycin precedes isoniazid exposure than when the 
two drugs and the bacilli are brought together at the same time. 
In experiments in which pyrazinamide and isoniazid were given sequentially 
the fact that the tubercle bacilli had been subsisting in the animals for 4 weeks 
when pyrazinamide was started did not appear to be a  determining factor in 
the production of the vanishing phenomenon. For the phenomenon could be 
produced when pyrazinamide was started on the 1st day of infection provided 
that a companion drug was also given. By the same token, a  conspicuous fea- 
ture of pyrazinamide action was the fact that it was equally effective against 
populations of tubercle bacilli which had been subsisting in the mice for 21 
days as it was against freshly introduced bacilli, Indeed there was an appre- 
ciable difference between pyrazinamide (with or without a  companion drug) 
and isoniazid in this respect. 
There are  certain prominent characteristics of the 21  day infection which 
might conceivably influence the over-all effectiveness of an antimicrobial drug. 
The census of tubercle bacilli is higher at that time, the inflammatory response 
and the microbial population are both more advanced and the host-parasite 
interaction has attained a crude equilibrium as evidenced by the stabilization 
and ensuing slight fall in the microbial census. The influence of any of these 
factors might be exerted directly on the parasite by rendering it more or less 
susceptible to a  particular drug; in addition, the inflammatory environment 
might exert a direct influence on drug activity. 
The size of the microbial population may have influenced the action of iso- 
niazid in the 21  day infection, but population size per se had no discernible 
influence on the action of pyrazinamide. In the 21 day experiments, the popu- 
lations of tubercle  bacilli had  just  reached  the peak  size  in both  lung and 800  FATE  OF  MYCOBACTERIUM  TUBERCULOSIS  IN  TISSUES 
spleen at the time pyrazinamide was started.  In ex~periments giving the single 
drugs in sequence, however, at the time pyrazinamide was started,  the popula- 
tions  were  relatively  low because  of a  preceding 4  week period  of  isoniazid. 
Nevertheless,  in both  experimental  situations,  the pyrazinamide  appeared  to 
exert maximal activity as judged by production of the vanishing phenomenon. 
The role of the biochemical environment of the infected lesion with respect to host 
resistance (10, 1  I, 13) and to antimicrobial drug action (5, 12) has been the subject of 
several recent discussions.  In the particular case of pyrazinamide it has been observed 
that the action of the drug on tubercle bacilli  of human origin became demonstrable 
in  vitro  only in  environments  comparable  in  their  acidity  with  those presumably 
present in necrotic lesions or the interior of monocytes (5). Such acidic environments 
did not cause the Ravenel strain of bovine origin to become susceptible to the drug. 
Mackaness has studied this question in a previously reported experimental system 
(14,  15) for the observation of tubercle bacilli  situated within monocytes in vitro. He 
has found (16)  s that tubercle bacilli of human origin, subsisting intracellularly in vitro, 
were completely inhibited by pyrazinamide concentrations of 12.5 /~g. per ml. in the 
extracellular  environment.  The  Branch  strain  of  bovine  tubercle  bacilli  was  not 
inhibited  by pyrazinamide  in  these  circumstances  even  when  considerably higher 
pyrazinamide concentrations were tested. The extracellular fluid environment in the 
Mackaness system is maintained at a pH of 7.0 throughout the experiment. In this 
environment,  the  monocytes remain  viable and  capable  of phagocytizing tubercle 
bacilli during the 28 day experimental period. In this situation, therefore, pyrazinamide 
is introduced into an environment (extracellularly) at a pH range in which it should not 
have demonstrable activity for human tubercle bacilli. The drug then diffuses from that 
extracellular  environment into the cell and in these circumstances is inhibitory  for 
tubercle bacilli of human, but not of bovine, origin which are is residence there. 
Thus there are two environments in which the inhibitory action of pyrazinamide on 
tubercle  bacilli  of human  origin can occur; an  extracellular  environment which  is 
sufficiently acidic; and the interior of monocytes in which there presumably is a low 
pH range. Whether the two environments operate by the same  mechanism, i.e.  the 
influence of acidity on drug or the tubercle bacilli,  cannot be stated at present. 
Pyrazinamide is  thus  capable of exerting an effect on tubercle bacilli of human 
origin: in acidic environments; within monocytes; after 21 days of growth in mice; and 
after previous or concurrent exposure to isoniazid in mice. Moreover, with a companion 
drug, pyrazinamide is as effective against tubercle bacilli of human origin in the mouse 
spleen as in the mouse lung. The drug is not effective against tubercle bacilli of bovine 
origin in  acidic environments,  within  monocytes,  or  in  experimental  infections in 
animals.  Moreover, it is not effective against human  tubercle  bacilli  in vitro when 
tested within the physiologic range of pH. Pyrazinamide is also not effective, even in 
the acidic environments in vitro against tubercle bacilli  of human origin which had 
resumed multiplication in the mouse during prolonged therapy with pyrazinamide 
alone. 
8 The writers are indebted to Dr. G. B. Mackaness of the Australian National University 
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These observations suggest that the pyrazinamide susceptibility  of an in- 
dividual tubercle  bacillus  is  closely  related  to its  capacity to  undergo some type 
of specific  alteration in response to environmental  influences including the 
other antituberculous drugs present in the environment.  The two strains  of 
bovine origin studied, and a tiny minority  of the H37Rv  strain of human 
origin,  lack or lose  this  capacity to  undergo the  specific  alteration.  The majority 
of the cells in human  strains  maintain this capacity to assume the altered 
state even after  a 21 day period of maturation in the mouse. The alternative 
possibility  that it is the drug itself  which is "activated" in some way by the 
environmental influences  cannot be excluded. This does not seem likely how- 
ever, both because of the apparent diversity of the environments of demon- 
strable effectiveness  and the lack of demonstrable activity  on tubercle  bacilli 
of bovine origin. 
With respect  to the vanishing of tubercle  bacilli  the only influence which 
has been demonstrated to determine pyrazinamide effectiveness has been the 
previous or concurrent exposure of the tubercle bacilli to another antitubercu- 
Ions drug,  which in most cases, was isoniazid. It has been reported  (9)  that 
isoniazid-resistant  tubercle  bacilli are unusually susceptible  to  pyrazinamide 
in  vitro.  Only two isoniazid-resistant  strains were used in the  present  study 
in vivo and in neither case did the tubercle  bacilli disappear  from the mouse 
tissues during the administration of pyrazinamide alone. 
It has not yet been determined whether the observed relapse rate of approxi- 
mately one-third of the infections 90 days after completion  of therapy could 
be  significantly  raised  by prolongation  of  the  posttreatment period  of ob- 
servation or lowered by prolongation  of the treatment. Thus, it has not yet 
been established  whether the tuberculous  infection  had actually been  elimi- 
nated, by pyrazinamide and a  companion  drug, in two-thirds of the animals 
and persisted  in latent form only in the remainder,  or whether the infection 
remained latent in all. Studies directed to these questions are now in progress 
with particular emphasis on the use of methods known to be capable of pro- 
ducing the emergence of infections from the latent state (17, 18). 
SUM~fARY 
Populations of tubercle  bacilli  of human origin  exposed in viva  to  pyrazinam- 
ide and a companion drug,  vanished from the tissues  of the mouse in so far as 
could be determined by microscopy,  culture, or guinea pig subinoculation. 
The vanishing did not represent a complete elimination of the tubercle  bacilli 
from all  the animals. 90 days after  the completion of treatment, tubercle  bacilli 
could be cultured from approximately one-third of the animals examined at 
that time. This complete disappearance of the tubercle  bacilli  thus meets the 
definition  of  a truly/atent  infection  in that the infection  is  present but is  hidden 
beyond the limits  of diagnostic reach. All but one of the strains  of tubercle 802  leATE  017 MY.COBACTERIUM  TUBERCULOSIS  IN  TISSUES 
bacilli which survived in the animals and were detectable in the posttreatment 
period, were susceptible to pyrazinamide when tested under appropriate con- 
ditions in vitro. 
Only two factors could be identified which were essential for the uniform oc- 
currence  of  the  disappearance  of tubercle  bacilli:  the  administration of the 
pyrazinamide in a high daily dosage for at least eight of a total of 12 weeks of 
antimicrobial therapy; and the concurrent or prior exposure of the microbial 
populations to  isoniazid or in some cases  to other antituberculous drugs. 
The observations suggest that the ability of pyrazinamide-containing chemo- 
therapies  to  bring about  the disappearance  of a  tubercle bacillus is  closely 
related to the occurrence of some alteration in the bacillus, essential for maxi- 
mal pyrazinamide action, in response  to environmental influences, including 
other antituberculous drugs present in the environment. 
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